Autoimmune hemolytic anemia: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
imported>Pat Palmer (adding subpages) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
In [[hematology]], '''{{PAGENAME}}''' is an "acquired hemolytic anemia due to the presence of [[autoantibody|autoantibodies]] which agglutinate or lyse the patient's own [[red blood cell]]s."<ref>{{MeSH}}</ref> | {{subpages}} | ||
In [[hematology]], '''{{PAGENAME}}''' (AIHA) is an "acquired hemolytic anemia due to the presence of [[autoantibody|autoantibodies]] which agglutinate or lyse the patient's own [[red blood cell]]s."<ref>{{MeSH}}</ref> | |||
==Classification== | ==Classification== | ||
| Line 12: | Line 13: | ||
==Treatment== | ==Treatment== | ||
As of 2010, no [[randomized controlled trial]]s were available.<ref name="pmid21778343">{{cite journal| author=Crowther M, Chan YL, Garbett IK, Lim W, Vickers MA, Crowther MA| title=Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. | journal=Blood | year= 2011 | volume= 118 | issue= 15 | pages= 4036-40 | pmid=21778343 | doi=10.1182/blood-2011-05-347708 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21778343 }} </ref> Subsequent studies are below. | |||
[[Rituximab]], a [[monoclonal antibody]], was found to be safe by a [[systematic review]] of 21 studies, although only one was a [[randomized controlled trial]]s.<ref name="pmid25497766">{{cite journal| author=Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet AS et al.| title=Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. | journal=Autoimmun Rev | year= 2014 | volume= | issue= | pages= | pmid=25497766 | doi=10.1016/j.autrev.2014.11.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25497766 }} </ref> | [[Rituximab]], a [[monoclonal antibody]], was found to be safe by a [[systematic review]] of 21 studies, although only one was a [[randomized controlled trial]]s.<ref name="pmid25497766">{{cite journal| author=Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet AS et al.| title=Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. | journal=Autoimmun Rev | year= 2014 | volume= | issue= | pages= | pmid=25497766 | doi=10.1016/j.autrev.2014.11.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25497766 }} </ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Latest revision as of 12:55, 8 September 2020
In hematology, Autoimmune hemolytic anemia (AIHA) is an "acquired hemolytic anemia due to the presence of autoantibodies which agglutinate or lyse the patient's own red blood cells."[1]
Classification
- Autoimmune hemolytic anemia
- Direct antiglobulin ("Coombs") test-negative
- Direct antiglobulin ("Coombs") test-positive
- Cold agglutinin disease[2]
Diagnosis
- Red-blood-cell-bound immunoglobulin G[3]
- Coombs' test, using the direct method, may have 97% sensitivity for detecting warm antibodies.[4][5]
Treatment
As of 2010, no randomized controlled trials were available.[6] Subsequent studies are below.
Rituximab, a monoclonal antibody, was found to be safe by a systematic review of 21 studies, although only one was a randomized controlled trials.[7]
References
- ↑ Anonymous (2024), Autoimmune hemolytic anemia (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Berentsen S, Tjønnfjord GE (2012). "Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia.". Blood Rev 26 (3): 107-15. DOI:10.1016/j.blre.2012.01.002. PMID 22330255. Research Blogging.
- ↑ Kamesaki T, Oyamada T, Omine M, Ozawa K, Kajii E (2009). "Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia.". Am J Hematol 84 (2): 98-101. DOI:10.1002/ajh.21336. PMID 19105232. Research Blogging.
- ↑ Worlledge SM, Blajchman MA (1972). "The autoimmune haemolytic anaemias.". Br J Haematol 23: Suppl:61-9. PMID 4567200. [e]
- ↑ Allgood JW, Chaplin H (1967). "Idiopathic acquired autoimmune hemolytic anemia. A review of forty-seven cases treated from 1955 through 1965.". Am J Med 43 (2): 254-73. PMID 6034957. [e]
- ↑ Crowther M, Chan YL, Garbett IK, Lim W, Vickers MA, Crowther MA (2011). "Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults.". Blood 118 (15): 4036-40. DOI:10.1182/blood-2011-05-347708. PMID 21778343. Research Blogging.
- ↑ Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet AS et al. (2014). "Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.". Autoimmun Rev. DOI:10.1016/j.autrev.2014.11.014. PMID 25497766. Research Blogging.